Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

Michael Recht, L. Nemes, M. Matysiak, M. Manco-Johnson, J. Lusher, M. Smith, P. Mannucci, C. Hay, T. Abshire, A. O'Brien, B. Hayward, C. Udata, D. A. Roth, S. Arkin

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII'. Together they form a unique fingerprint.

Medicine & Life Sciences